Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens announced today that its Chief Executive Officer, Alexander Belcredi, will present at the Biotech Showcase 2020 Conference
BiotechnologyConferences

PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens announced today that its Chief Executive Officer, Alexander Belcredi, will present at the Biotech Showcase 2020 Conference

January 8, 2020 5:35 PM

Presenting at the Biotech Showcase, 2020 Tuesday, January 14, 2020 10:30 am PST PhagoMed's presentation at Biotech Showcase will cover its proprietary engineering platform, its lead assets and an outlook to the plans for 2020 and beyond VIENNA / ACCESSWIRE / January 8, 2020 / PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens in antibiotic resistance and microbiome settings, announced...

Read more
Cure Rare Disease: A Year in Review
BiotechnologyCompany Update

Cure Rare Disease: A Year in Review

January 8, 2020 9:00 AM

Significant Milestones Fuel Development of Customized Therapeutics for Duchenne muscular dystrophy BOSTON,MA / ACCESSWIRE / January 8, 2020 / Cure Rare Disease (CRD), the emerging, Boston-based nonprofit on a mission to develop precision medicine for rare diseases, is pleased to provide an annual review of its activities and accomplishments in 2019. Successful fundraising efforts have allowed CRD to accelerate their drug development plan,...

Read more
A Key Message from the New CEO, Jarrett Malnarick
BiotechnologyCompany Update

A Key Message from the New CEO, Jarrett Malnarick

January 8, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / January 8, 2020 / Experion Holdings Ltd. (the "Corporation" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) Given the recent leadership change announced on January 6, 2020, Experion Holdings Ltd.'s newly appointed CEO and Director, Jarret Malnarick, is pleased to share some immediate strategy and objectives going forward for the Company As the Canadian cannabis industry continues to be challenged with...

Read more
Hancock Jaffe Reports Positive Results for 6 Month CoreoGraft Animal Feasibility Study
BiotechnologyCompany Update

Hancock Jaffe Reports Positive Results for 6 Month CoreoGraft Animal Feasibility Study

January 8, 2020 8:31 AM

Grafts Open and Fully Functional at 6 Months IRVINE, CA / ACCESSWIRE / January 8, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced positive results from its six (6) month CoreoGraft animal feasibility study. At thirty (30), ninety (90), and one hundred and eighty (180) days post CoreoGraft bypass surgeries, all grafts were patent (open) when the...

Read more
NanoValent Pharmaceuticals Announces the Publication of US Patent Targeted Polymerized Nanoparticles for Cancer Treatment
BiotechnologyCompany Update

NanoValent Pharmaceuticals Announces the Publication of US Patent Targeted Polymerized Nanoparticles for Cancer Treatment

January 8, 2020 8:00 AM

NanoValent will Deliver a Corporate Presentation at the IvyFON Family Office 2020 Outlook Conference, January 14th in San Francisco during the JP Morgan Healthcare Conference Week SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2020 / NanoValent Pharmaceuticals, Inc., a development stage cancer focused pharmaceutical company progressing a new class of targeted nanospheres (TNS) based therapies today announced the publication of United States...

Read more
AML, Ewing Sarcoma, ARDS, HIV, IO, Phages, Infections, Diagnostics and Alzheimer’s; All ready to move to the next clinical level. All at the JP Morgan Healthcare Conference Week
BiotechnologyCompany Update

AML, Ewing Sarcoma, ARDS, HIV, IO, Phages, Infections, Diagnostics and Alzheimer’s; All ready to move to the next clinical level. All at the JP Morgan Healthcare Conference Week

January 8, 2020 8:00 AM

CHICAGO, IL / ACCESSWIRE / January 8, 2020 / Content Carnivores, LLC, a creative marketing firm deploying proprietary technology, category and creative expertise in regulated industries is supporting 10 clients who are participating at the Biotech Showcase™ 2020, investor conference and/or other events in San Francisco being held simultaneously as the JP Morgan Healthcare Conference, January 12 -16, 2020. To view the full release with...

Read more
Pieris Pharmaceuticals Announces Leadership Update
BiotechnologyCompany Update

Pieris Pharmaceuticals Announces Leadership Update

January 8, 2020 8:00 AM

BOSTON, MA / ACCESSWIRE / January 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced an update to its senior leadership team. Within research and development, Ingmar Bruns, M.D., Ph.D., previously serving as Vice President, Clinical Development...

Read more
Dyadic Reports Continued Positive Business Trends and  Scientific Results in Fourth Quarter 2019
BiotechnologyCompany Update

Dyadic Reports Continued Positive Business Trends and Scientific Results in Fourth Quarter 2019

January 6, 2020 4:10 PM

Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal Study New Collaboration Agreement with Top Ten Pharmaceutical Company Expanded Research Relationship with Leading Pharmaceutical Company IIBR Collaboration Achieved Expression of Fc-fusion Enzyme to Counter Biological Attacks  Glycoengineering Data Reinforces Company's Accelerated Glyco Strategy Two New Patent Applications JUPITER, FL / ACCESSWIRE / January 6, 2020 / Dyadic...

Read more
Molecular Partners to Present at the 38th Annual J.P. Morgan Healthcare Conference
BiotechnologyConferences

Molecular Partners to Present at the 38th Annual J.P. Morgan Healthcare Conference

January 6, 2020 11:30 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / January 6, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 9:00 AM Pacific Standard Time (12:00 PM Eastern Time; 6:00 PM CET). The presentation, followed by a Q&A session, will be...

Read more
Edesa Biotech Announces $4.36 million Registered Direct Offering
BiotechnologyFinancing

Edesa Biotech Announces $4.36 million Registered Direct Offering

January 6, 2020 9:21 AM

TORONTO, ON / ACCESSWIRE / January 6, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive securities purchase agreements with certain institutional and accredited investors as well as company insiders in a registered direct offering of an aggregate of 1,355,380 common shares. The price per share for investors other than investors that are officers, directors,...

Read more
Experion Announces Leadership Change
BiotechnologyCompany UpdateManagement Changes

Experion Announces Leadership Change

January 6, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / January 6, 2020 / Experion Holdings Ltd. (the "Corporation" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) announces the departure of Chief Executive Officer and director, Jay Garnett, effective January 3, 2020. Experion's board of directors (the "Board") would like to thank Mr. Garnett for his service. The Board has appointed Mr. Jarrett Malnarich as Chief Executive Officer and a director of the...

Read more
Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma
BiotechnologyInvestor Relations

Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma

December 27, 2019 1:00 AM

ZURICH-SCHLIEREN / ACCESSWIRE / December 27, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug Administration (FDA) for its novel therapeutic, MP0250, for the treatment of Multiple Myeloma. MP0250 is a first-in-class, tri-specific multi-DARPin® drug candidate neutralizing VEGF-A...

Read more
VenoValve Abstract Published in January 2020 Edition of Journal of Vascular Surgery
BiotechnologyCompany Update

VenoValve Abstract Published in January 2020 Edition of Journal of Vascular Surgery

December 20, 2019 8:31 AM

Presentation from Abstract to be Delivered at the Southern Association of Vascular Surgery Conference January 8 to 11 in Palm Beach, Florida IRVINE, CA / ACCESSWIRE / December 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that an abstract entitled Results of First-in-Human Implantation of a Prosthetic Venous Valve has been...

Read more
Frelii Announces International License and Profit Sharing Agreement
BiotechnologyPartnerships

Frelii Announces International License and Profit Sharing Agreement

December 19, 2019 10:45 AM

Frelii Announces International License and Profit Sharing Agreement Company expands its genome discovery AI footprint into Canada LEHI, UT / ACCESSWIRE / December 19, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today it has signed a License and Profit Sharing Agreement ("Agreement) with...

Read more
Midatech Pharma PLC Announces Receipt of NASDAQ Notice
BiotechnologyRegulatory

Midatech Pharma PLC Announces Receipt of NASDAQ Notice

December 16, 2019 6:20 PM

LONDON, UK / ACCESSWIRE / December 16, 2019 / Midatech (AIM:MTPH)(NASDAQ:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products, announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"), dated 11 December 2019, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued...

Read more
Edesa Biotech Reports Financial Results for Short Period Fiscal Year
BiotechnologyEarnings

Edesa Biotech Reports Financial Results for Short Period Fiscal Year

December 12, 2019 4:30 PM

TORONTO, ON / ACCESSWIRE / December 12, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the nine-month period ended September 30, 2019 and provided an update on its business. Edesa recently enrolled the first patient in a Phase 2b clinical study of its lead product candidate, EB01. The company is developing EB01 as a monotherapy for patients with chronic allergic...

Read more
DECN in Major Revenue Move Decides to Include New GenAccord! Product Line in its Upcoming Strategic Agreement at the Request of Strategic Partner
BiotechnologyPartnerships

DECN in Major Revenue Move Decides to Include New GenAccord! Product Line in its Upcoming Strategic Agreement at the Request of Strategic Partner

December 12, 2019 8:55 AM

COMPANY TO DISCUSS THIS BUSINESS MOVE IN FURTHER DETAIL EARLY NEXT WEEK, SHORTLY THEREAFTER DECN WILL POST FORECASTS ON ITS WEB SITE LOS ANGELES, CA / ACCESSWIRE / December 12, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory...

Read more
Molecular Partners’ R&D Day in New York City highlights pipeline progress of DARPin(R) therapeutic candidates and provides updates on research activities
BiotechnologyInvestor Relations

Molecular Partners’ R&D Day in New York City highlights pipeline progress of DARPin(R) therapeutic candidates and provides updates on research activities

December 12, 2019 1:00 AM

Nicolas Leupin, CMO, highlights progress in the development of all three DARPin® product candidates in clinical trials: MP0250 in phase 2 clinical development, MP0274 in phase 1, and MP0310 in co-development with Amgen Recent data presented for MP0250 in relapsed/refractory multiple myeloma at ASH underline the drug's unique ability to complement standard of care through its novel mechanism of action, focusing on the tumor...

Read more
Molecular Partners Presents Updated Results of MP0250 in Patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology Annual Meeting
BiotechnologyCompany UpdateInvestor Relations

Molecular Partners Presents Updated Results of MP0250 in Patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology Annual Meeting

December 7, 2019 7:00 AM

Poster highlights Overall Response Rate (ORR) of 45% in heavily pretreated MM population Strong evidence of durable and deepening responses with ongoing treatment in excess of 9 months in multiple patients, including one patient who achieved a Complete Response (CR) Mechanism of action targeting the microenvironment, inhibiting two signaling pathways, affecting tumor cell growth Additional data to be presented at Molecular Partners' R&D...

Read more
CEL-SCI Corporation to Present at The LD Micro  Main Event (XII)
BiotechnologyConferences

CEL-SCI Corporation to Present at The LD Micro Main Event (XII)

December 6, 2019 9:00 AM

VIENNA, VA / ACCESSWIRE / December 6, 2019 / CEL-SCI Corporation (NYSE American:CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 12th annual LD Micro Main Event on Tuesday, December 10, 2019 at 2:00 PM PST or 5:00 PM EST. The Chief Executive Officer, Geert Kersten, will be presenting and meeting with investors. To access the live webcast and subsequent archived recordings for the presentation,...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?